SARS-CoV-2 と COVID-19 に関するメモ・備忘録
アメリカで2020年から2021年にかけて増加した交通事故死はコロナウイルス感染の累積数と強く相関しており、長期障害による認知障害が原因と仮説することが十分に可能で、感染したことのある人は出来るだけ車の運転は控えた方が良いというイェール大学の研究。https://t.co/ie5TWQBrKe
— Angama (@Angama_Market) October 18, 2023
後遺症による事故…学校・園で子どもがうつしあい家庭に持ち帰るパターンはかなり多い。警鐘ならしてる方たちの邪魔をして、笑顔ガーと奪マスクして感染拡大促進させてる人たちは間接的に、こういう事例に手を貸しているってわけだ。両親が事故起こしたら子どもの笑顔なんて、たちまち消えるだろうに。 https://t.co/imobs0GYJo pic.twitter.com/ImBCJqI0NM
— ぽあろ (@I5McNNdZnCXsI5u) October 18, 2023
電車や飛行機の操縦は大丈夫なのか心配です。
— Angama (@Angama_Market) October 19, 2023
新型コロナ感染が爆発的に増えた第8波以降に弊店周りでやたらと交通事故が多発してないかと肌感で感じてましたが……病態として脳・神経病変から認知機能にも自覚なく障害が出るので納得するしかないです。 https://t.co/fUbV60EkZq
— うじー@感染対策魔人はマスク着用と科学で対処 (@medical_for_all) October 18, 2023
こういう研究はたぶん永久に査読を通ることはないんでしょうけど、良い分析だと思います。
— Angama (@Angama_Market) October 19, 2023
大切な視点なのですよね、これからの世界がまずいなと俯瞰するためにも。
— うじー@感染対策魔人はマスク着用と科学で対処 (@medical_for_all) October 19, 2023
これは十分あり得る話だと思う。
バスの運転手さんの不足によるバス便の減少も、要は後遺症で運転のできないレベルと自覚をなさって泣く泣くハンドルを手放した方も多いから、ということじゃないのかあれ。バス中の換気の悪さとノーマスクの多さ、夏には幾らでも話題が拾えたし。 https://t.co/CQaOIq0FRM
— ただの11 (@11_tadano) October 18, 2023
バスの運転手はコロナウイルス入院のリスクが普通の約2倍というニュースがありましたね。https://t.co/C7e5MoGHGO
— Angama (@Angama_Market) October 19, 2023
やっぱりきたな、という内容。まだプレプリントだけど。これが、というか、これも、コロナの怖いところだよ。 https://t.co/9CQahvk89Y
— چیفومی (@chifumi_k) October 18, 2023
◆Did “long COVID” increase road deaths in the U.S.?【medRxiv 2023年10月11日】
Abstract
Objective To examine data on COVID-19 disease associated with a 10 percent increase in U.S. road deaths from 2020 to 2021 that raises the question of the potential effect of pandemic stress and neurological damage from COVID-19 disease.
Methods Poisson regression was used to estimate the association of recent COVID-19 cases, accumulated cases, maximum temperatures, truck registrations, and gasoline prices with road deaths monthly among U.S. states in 2021. Using the regression coefficients, changes in each risk factor from 2020 to 2021 were used to calculate expected deaths in 2021 if each factor had remained the same as in 2020.
Results Corrected for the other risk factors, road deaths were associated with accumulated COVID-19 cases but not cases in the previous month. More than 20,700 road deaths were associated with the changes in accumulated COVID-19 cases but were substantially offset by about 19,100 less-than-expected deaths associated with increased gasoline prices.
Conclusions While more research is needed, the data are sufficient to warn people with “long COVID” to minimize road use.
What is already known about this topic Previous short-term fluctuations in road deaths are related to changes in temperature, fuel prices, and truck registrations.
What this study adds Corrected for other risk factors, the monthly changes in road deaths from 2020 to 2021 in U.S. states were associated with cumulative COVID-19 cases.
How this study might affect research, practice, or policy Studies are needed to distinguish the potential relative effects of neurological damage as well as the stress of coping with the pandemic on driving, walking, and bicyclist behavior. Warning people with “long covid” about road risk is warranted.
Introduction
While many countries experienced a reduction in road deaths during the first year of the COVID-19 pandemic, deaths increased 6.9 percent from 2019 to 2020 in the U.S. In 2021 road deaths in the U.S. increased 10.5 percent above those experienced in 2020. Analysis of the 2020 increase among U.S. states found most of it correlated to changes in temperatures, truck registrations, and fuel prices. The increase month by month was not significantly correlated with COVID-19 cases in the prior month among U.S. states, controlling statistically for the three mentioned risk factors. Fluctuations in monthly state road deaths have been related consistently to changes in temperatures, truck registrations, and fuel prices for decades. Fatal vehicle crashes occur disproportionately at night and on weekends when traffic is lighter. Temperature and gas prices are proxy variables for discretionary travel. Trucks are disproportionately involved in fatal crashes.
In 2021 The U.S. average maximum temperature averaged monthly among the states, changed little from the average in 2020. Truck registrations increased 4.4 percent but fuel prices rose 38 percent. The latter should have more than offset the effect of the increase in truck registrations on the road death rate per population. The possible role of COVID-19 as a risk factor for the increased road deaths in 2021 deserves a closer look.
The neurological changes in people with COVID-19 disease include the potential for an increase in road deaths. A wide variety of neurological symptoms occur in the aftermath of infection of many people and changes in the brains of those infected have been observed. Rather than an association of recent COVID-19 cases and road deaths, a “long covid” effect would be associated with accumulated cases. The purpose of this paper is to report a test of the hypothesis that differences in road deaths among U.S. states in 2021 are associated with accumulated COVID-19 cases, controlling statistically for the other mentioned risk factors.
コロナウイルス長期障害の発生率が5%だと仮定しても、次の10年間に長期障害者は現在の3倍以上に増加し、全世界で約2億人が発症するという予測。心臓疾患を抱える人口とほぼ同じ規模になることになる。
Long COVID research risks losing momentum – we need a moonshot https://t.co/1jsGGmHd4z
— Angama (@Angama_Market) October 20, 2023
コロナウイルスが動脈細胞に感染→動脈プラークに感染→除去するために集まったマクロファージに感染→泡沫細胞に感染→感染細胞がサイトカインを放出→さらにプラークが拡大→拡大したプラークに感染、という流れですね。
— Angama (@Angama_Market) October 20, 2023
ツイートは出来ませんでしたが、散発的にデルタがアウトブレイクを起こして下水中のウイルス量を増やしているという論文もありました。もう変異株単位で注目するやり方では現実を追えないと思います。
— Angama (@Angama_Market) October 20, 2023
コロナウイルス死亡患者の解剖の結果、各部位からそれぞれ別の変異株が見つかったという研究もあるので、一人の感染者に変異株一種類しかいないという見方はもう非現実的だと思います。一度に複数株に感染して、感染中に別の変異株に感染して、途中でさらに変異するという状態ではないでしょうか。
— Angama (@Angama_Market) October 24, 2023
コロナウイルスは「音」みたいなもので、近くにある細胞には全て感染すると思ってます。
— Angama (@Angama_Market) October 20, 2023
北半球でコロナウイルス入院数と死亡数が増加を続けているというWHOの発表。 https://t.co/GT7Vqt5FLO
— Angama (@Angama_Market) October 24, 2023
コロナウイルスは血液脳関門上のカベオラという小さな陥没を増加させ、透過性を上昇。また、海馬で白血球を血管内皮に貼り付けるVCAM1という分子とT細胞の浸潤を起こし、学習と記憶に障害をもたらすことが分かったという研究。https://t.co/OpjMe0QW3j
— Angama (@Angama_Market) October 24, 2023
◆Caveolin-1 mediates neuroinflammation and cognitive impairment in SARS-CoV-2 infection【bioRxiv 2023年10月18日】
Abstract
Leukocyte infiltration of the CNS can contribute to neuroinflammation and cognitive impairment. Brain endothelial cells regulate adhesion, activation, and diapedesis of T cells across the blood-brain barrier (BBB) in inflammatory diseases. The integral membrane protein Caveolin-1 (Cav-1) critically regulates BBB permeability, but its influence on T cell CNS infiltration in respiratory viral infections is unknown. In this study, we sought to determine the role of Cav-1 at the BBB in neuroinflammation in a COVID-19 mouse model. We used mice genetically deficient in Cav-1 to test the role of this protein in T cell infiltration and cognitive impairment. We found that SARS-CoV-2 infection upregulated brain endothelial Cav-1. Moreover, SARS-CoV-2 infection increased brain endothelial cell vascular cell adhesion molecule-1 (VCAM-1) and CD3+ T cell infiltration of the hippocampus, a region important for short term learning and memory. Concordantly, we observed learning and memory deficits. Importantly, genetic deficiency in Cav-1 attenuated brain endothelial VCAM-1 expression and T cell infiltration in the hippocampus of mice with SARS-CoV-2 infection. Moreover, Cav-1 KO mice were protected from the learning and memory deficits caused by SARS-CoV-2 infection. These results indicate the importance of BBB permeability in COVID-19 neuroinflammation and suggest potential therapeutic value of targeting Cav-1 to improve disease outcomes.
Introduction
COVID-19 is associated with leukocyte infiltration of the CNS. Some data suggests that T cells in the CNS contribute to neuroinflammatory processes in COVID-19; for example, high perivascular T cell density spatially correlates with microglial nodules enriched in disease-associated proinflammatory phenotypes. Immunopathologic contribution of T cell infiltration to microglial activation and neurodegeneration is commonly observed in CNS diseases. Hippocampal T cell infiltration particularly contributes to cognitive impairment, consistent with the important role of the hippocampus in cognition. Disorders of cognition are frequent in COVID-19. The contribution of hippocampal T cell infiltration to cognitive impairment in COVID-19 is incompletely understood.
Blood brain barrier (BBB) endothelial cells regulate T cell infiltration of the CNS. One way to address how T cell interactions at the BBB influence cognitive outcomes in COVID-19 is to assess function of specific proteins. Here, we focused on Caveolin-1 (Cav-1). Cav-1 promotes BBB permeability by facilitating endocytosis and transcellular transcytosis. Adhesion molecules are essential for the adhesion between leukocytes and endothelial cells that ultimately leads to diapedesis into inflamed tissues. Cav-1 contributes to the scaffolding, membrane retention, and recycling of leukocyte adhesion molecules including vascular cell adhesion molecule (VCAM)-1 and Intracellular Adhesion Molecule (ICAM)-1. Cav-1 upregulation in disease contributes to BBB leakage and neuroinflammation. Indeed, we and others have shown that Cav1 promotes migration of proinflammatory T cells across the BBB, whereas loss of endothelial Cav-1 impairs T cells and neutrophil adhesion and transmigration. Moreover, suppressing Cav-1 reduces proinflammatory leukocyte infiltration, neuroinflammation, and neurodegeneration.
Cav-1 might contribute to neuroinflammation in COVID-19. Strikingly, Cav-1 is upregulated in forebrains of COVID-19 decedents. Transcellular BBB permeability is described in models of COVID-19. These data raise the possibility that cerebrovascular Cav-1 upregulation might contribute to COVID-19 neuropathogenesis. However, the extent to which Cav-1 contributes to neuroinflammation and cognitive impairment in COVID-19 has not been tested.
Thus, the goal of the present study was to evaluate the extent to which Cav-1 contributes to cognitive impairment by promoting BBB permeability to T cells in a COVID-19 mouse model. We found that mild respiratory SARS-CoV-2 infection increased expression of Cav-1 and VCAM-1 on brain endothelial cells. This was accompanied by T cell neuroinflammation in the hippocampus and learning/memory deficits in infected mice. Genetic deficiency in Cav-1 offered protection from SARS-CoV-2 induced neuroinflammation and memory deficits. These data indicate that Cav-1-mediated BBB permeability to T cells is increased during acute SARS-CoV-2 respiratory infection and may contribute to neuropathology and cognitive impairment in COVID-19.
サワイ製薬のこと。
安過ぎる薬価と薬の供給不安が念頭にあるから、擁護っぽい意見も見かけるけど。
この2010年の下り読んで、『あぁ上層部から指示あったな(証拠残らないように電話で)』と思わず、報道通り「末端の人が勝手にやった」と思ってるなら、理解できんわ。 pic.twitter.com/PU1Jgv6JBw
— ramos2 (@ramos262740691) October 23, 2023
①原因究明を研究部門に投げたら何故か『カプセル入れ替えたらイケるぜ!』という「不正のやり方発明」結果のお返事。申請資料書く研究者達は初めからry
②それを全責任を持つべき本社の偉い人(品質責任者)にメール。『何故か返事が見当たらない』
いや。こんな重大案件無視される訳ねぇだろ…隠ry pic.twitter.com/i1ltuBK13R— ramos2 (@ramos262740691) October 23, 2023
古いカプセルで溶出しないこと分かったなら使用期限短く訂正すれば良かっただけの話で。単に仕事さぼっただけのビッグモーターじゃん。
こういうのを擁護したら、日本の医療に未来はねぇよ。というか日本の会社員に未来はねぇよ。
経営陣の責任。以上
— ramos2 (@ramos262740691) October 23, 2023
化血研を典型に悪質ですよねぇ。
30~40年前の昔はゼリアがいろいろ起した。— Hiroshi Makita Ph.D. 誰が日本のコロナ禍を悪化させたのか?扶桑社8/18発売中 (@BB45_Colorado) October 23, 2023
ほんと杜撰ですし、今回は末端の人が勝手にやった系でXという人物一人の勘違いに落とし込んでるのが気持ち悪いですね。
メールや文書が消されてるだけで、明らかに2010年に指示があって始まった作業でしょう。
カプセル新品に入れ替えるなんて面倒過ぎて試験者は自らやらないでしょう。— ramos2 (@ramos262740691) October 23, 2023
平畑先生によると、日本では、#コロナ後遺症 の患者さんが400万人はいると…@k_hirahata https://t.co/KHq8E6xbft
— Koichi Kawakami, 川上浩一 (@koichi_kawakami) October 22, 2023
平畑先生
糖尿病や高血圧等の特定疾患より後遺症患者さんを診るのは時間と手間がかかるし、勉強もしないといけない。しかし診療報酬は6分の1。だから後遺症患者さんを診る医療機関が増えないのではないか。この問題については以前より語られていて#コロナ後遺症 https://t.co/nietqcsl7H— くぅ (@itsukainuakani) October 22, 2023
小児におけるCOVID-19感染後の感染伝播期間について。
アメリカ、2022/4-9、7-18歳のCOVID-19 PCR陽性者76名対象。
68.4%はワクチン接種済。
咽頭スワブから感染性のあるウイルスが検出されたのは陽性日から中央値3日間。
陽性5日目では18.4%、10日目では3.9%に感染性が維持されていた。→— Sukuna (@SukunaBikona7) October 23, 2023
ワクチン接種歴による差はなし。また、追加接種の有無でも差はなし。https://t.co/WzAvN9XnQa
小児においてPCR陽性になった日を0日目として、5日目まで約2割に感染性のあるウイルスが検出されたと。
発症からPCR検査まである程度の期間があると考えられるので、発症翌日から5日目だと→— Sukuna (@SukunaBikona7) October 23, 2023
感染性のあるウイルスを持つ割合は少なくとも2割よりも高いだろう。
— Sukuna (@SukunaBikona7) October 23, 2023
◆Duration of SARS-CoV-2 Culturable Virus Shedding in Children【JAMA Network 2023年10月23日】
COVID-19 quarantine and self-isolation policies continue to interrupt education. These policies, while typically more stringent than for routine viral illnesses, are guided by few data; the duration of SARS-CoV-2 infectivity in children is largely unknown. One study found that nasopharyngeal samples from infected children, compared with adults, were half as likely to contain culturable virus.1 No study to date has examined viral shedding of the Omicron variant in children longitudinally. We evaluated duration of infectivity and its association with vaccination using live viral recovery over a 10-day window after a positive COVID-19 test result in children in Los Angeles County.
SARS-CoV-2: The Biological Acid that Devours Your Immune Alarm System 🧵
— Outbreak Updates (@outbreakupdates) October 24, 2023
When SARS-CoV-2 reaches MAVS, think of it as if battery acid has been poured onto the main electrical panel of a building.
2/
— Outbreak Updates (@outbreakupdates) October 24, 2023
This acid corrodes the internal workings of MAVS (Mitochondrial Antiviral-Signaling Protein), rendering them dysfunctional.
MAVS usually act like a relay station.
2/
— Outbreak Updates (@outbreakupdates) October 24, 2023
When your cells detect the presence of a virus, MAVS helps transmit that signal to other parts of the immune system.
They initiate a cascade of events that ultimately lead to the production of interferons such as IFN-β.
3/
— Outbreak Updates (@outbreakupdates) October 24, 2023
These interferons act like alarm bells, warning neighboring cells about the viral threat and activating various immune responses to fight off the invader.
4/
— Outbreak Updates (@outbreakupdates) October 24, 2023
However, the destructive effect of the virus causes MAVS to malfunction so severely that it can no longer send these critical signals to IFN-β.
5/
— Outbreak Updates (@outbreakupdates) October 24, 2023
As a result, the alarm system stays silent, and the body is left without its usual coordinated defense mechanisms to fight off the viral invasion.
6/
— Outbreak Updates (@outbreakupdates) October 24, 2023
◆ORF3c is expressed in SARS-CoV-2-infected cells and inhibits innate sensing by targeting MAVS【EMBO reports 2023年10月23日】
Abstract
Most SARS-CoV-2 proteins are translated from subgenomic RNAs (sgRNAs). While the majority of these sgRNAs are monocistronic, some viral mRNAs encode more than one protein. One example is the ORF3a sgRNA that also encodes ORF3c, an enigmatic 41-amino-acid peptide. Here, we show that ORF3c is expressed in SARS-CoV-2-infected cells and suppresses RIG-I- and MDA5-mediated IFN-β induction. ORF3c interacts with the signaling adaptor MAVS, induces its C-terminal cleavage, and inhibits the interaction of RIG-I with MAVS. The immunosuppressive activity of ORF3c is conserved among members of the subgenus sarbecovirus, including SARS-CoV and coronaviruses isolated from bats. Notably, however, the SARS-CoV-2 delta and kappa variants harbor premature stop codons in ORF3c, demonstrating that this reading frame is not essential for efficient viral replication in vivo and is likely compensated by other viral proteins. In agreement with this, disruption of ORF3c does not significantly affect SARS-CoV-2 replication in CaCo-2, CaLu-3, or Rhinolophus alcyone cells. In summary, we here identify ORF3c as an immune evasion factor of SARS-CoV-2 that suppresses innate sensing in infected cells.
#拡散希望 速報🔔 G2P-Japan🇯🇵の新しい研究成果「EG.5.1株(俗称 #エリス)のウイルス学的特性の解明」を、bioRxiv @biorxivpreprint に発表しました。
ちなみに、EG.5.1(とEG.5.1.1)は、こんな変異を持っている変異株です↓ 1/https://t.co/mYIdZDFQu4 pic.twitter.com/QfUL7Wu4w4— The Sato Lab (Kei Sato) (@SystemsVirology) October 23, 2023
① @jampei2 と @chainorato による分子系統学×流行動態の融合解析の結果、EG.5.1の持つふたつの変異、S:F456LとORF9b:I5Tのふたつが、この株の流行拡大に寄与していることが示唆されました。2/ pic.twitter.com/oz6Ntv29Wq
— The Sato Lab (Kei Sato) (@SystemsVirology) October 23, 2023
② いろいろな細胞を使った増殖試験の結果、EG.5.1(とEG.5.1.1)の増殖効率は、直近の流行株であるXBB.1.5とほぼ同等か、それよりも劣っていました。3/ pic.twitter.com/cmJw7pn0Ee
— The Sato Lab (Kei Sato) (@SystemsVirology) October 23, 2023
③ 3つの抗ウイルス薬、ニルマトレルビル(パキロビット®)、レムデシビル(ベクルリー®)、エンシトレルビル(ゾコーバ®)の効果を評価しました。その結果、どの薬もEG.5.1(とEG.5.1.1)に効果的でした。4/ pic.twitter.com/9XQym91CAs
— The Sato Lab (Kei Sato) (@SystemsVirology) October 23, 2023
④ スパイクタンパク質発現システムを使った融合力試験の結果、EG.5.1のスパイクの融合力は、直近の流行株であるXBB.1.5と同等でした。5/ pic.twitter.com/IEVIYjXCZm
— The Sato Lab (Kei Sato) (@SystemsVirology) October 23, 2023
⑤ EG.5.1のスパイクタンパク質の構造を、クライオ電子顕微鏡法で解析しました。図中Cに示すように、XBB.1.5のスパイクタンパク質と構造を比較すると、F456L変異により、いくつかのアミノ酸残基(P373など)の配置が異なることがわかりました。6/ pic.twitter.com/X19jTHGB17
— The Sato Lab (Kei Sato) (@SystemsVirology) October 23, 2023
⑥ ハムスターを用いた感染実験の結果、EG.5.1(とEG.5.1.1)の病原性は、直近の流行株であるXBB.1.5とほぼ同等でした。7/ pic.twitter.com/SJUwD9Y98W
— The Sato Lab (Kei Sato) (@SystemsVirology) October 23, 2023
⑦ EG.5.1に特徴的な変異のひとつである、ORF9bのI5T変異の影響も評価しました。ORF9bはインターフェロン応答を阻害する機能があることが報告されています。しかし、その活性はさほど強くなく、また、EG.5.1が獲得した変異も、その活性にほとんど影響を与えませんでした。8/ pic.twitter.com/xIR7b9n6W4
— The Sato Lab (Kei Sato) (@SystemsVirology) October 23, 2023
さらに、ORF9bのI5T変異がウイルス増殖に与える影響を評価するために、I5T変異を戻した変異体(ORF9b:T5I)、ORF9bを欠損した変異体(ORF9b KO)を人工合成し、いろいろな細胞を使った増殖試験をしました。その結果、いずれのORF9bの変異も、ウイルス増殖に大きな影響を与えませんでした。9/ pic.twitter.com/2EZCZtU2tR
— The Sato Lab (Kei Sato) (@SystemsVirology) October 23, 2023
ORF9b:I5Tが新型コロナの流行動態に与える効果については、実験的に検証が難しい事象なのかもしれません。もうひとつの特徴、S:F456Lについては、G2P-Japanの先行研究で、免疫逃避に重要な変異であることを明らかにしています。10/10https://t.co/3AuYsjfn0x
— The Sato Lab (Kei Sato) (@SystemsVirology) October 23, 2023
◆Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant【bioRxiv 2023年10月19日】
Abstract
In middle-late 2023, a sublineage of SARS-CoV-2 Omicron XBB, EG.5.1 (a progeny of XBB.1.9.2), is spreading rapidly around the world. Here, we performed multiscale investigations to reveal virological features of newly emerging EG.5.1 variant. Our phylogenetic-epidemic dynamics modeling suggested that two hallmark substitutions of EG.5.1, S:F456L and ORF9b:I5T, are critical to the increased viral fitness. Experimental investigations addressing the growth kinetics, sensitivity to clinically available antivirals, fusogenicity and pathogenicity of EG.5.1 suggested that the virological features of EG.5.1 is comparable to that of XBB.1.5. However, the cryo-electron microscopy reveals the structural difference between the spike proteins of EG.5.1 and XBB.1.5. We further assessed the impact of ORF9b:I5T on viral features, but it was almost negligible at least in our experimental setup. Our multiscale investigations provide the knowledge for understanding of the evolution trait of newly emerging pathogenic viruses in the human population.